Budesonide-Hydroxypropyl-β-Cyclodextrin Inclusion Complex in Poloxamer 407 and Poloxamer 407/403Systems: A Structural Study by Small Angle X-Ray Scattering (SAXS)
Abstract
Poloxamer (PL), copolymers composed of polyethylene oxide (PEO) and
polypropylene oxide (PPO) units, have been studied for several
applications considering them as tensoatives, stabilizers, solubilizers
and nano carriers. For pharmaceutical applications, they are of great
interest for the development of drug-delivery systems as unique or
binary systems (association of two types of PL) and for forming
supramolecular complexes with other molecules (i.e.
2-hydroxypropyl-p-cyclodextrin-HP-β-CD), especially for poorly soluble
drugs, such as budesonide (BUD), a glucocorticoid widely used for the
treatment of ulcerative colitis. This study reports the structural
studies, by Small Angle X-ray Scattering (SAXS), looking forward the
understanding of the mechanisms and models of interaction between BUD,
HP-β-CD or BUD-HP-β-CD inclusion complex and PL407 or its binary system,
PL407-PL403. The SAXS analysis revealed the systems organization in a
lamellar structure, for PL407 and PL407-PL403, even after addition of
HP-β-CD, BUD or the BUD-HP-β-CD inclusion complex. Those differences are
results of typical interactions between BUD or HP-β-CD with the
micellar core (PPO region), while the presence of inclusion complex is
observed on the micellar hydrated region (PEO). Those results are of
great interest on the study of physico-chemical aspects applied to the
development of drug-delivery formulations.
Abbreviations: PL: Poloxamer; PEO: Poly
Ethylene Oxide; PPO: Poly Propylene Oxide; BUD: Budesonide; SAXS: Small
Angle X-ray Scattering; UC: Ulcerative Colitis; CD: Cyclodextrins
Introduction
Systemic glucocorticoids have been traditionally used to induce
remission in patients with inflammatory bowel disease such as ulcerative
colitis (UC), due to their potent anti-inflammatory effects. However,
the wide range of adverse effects associated with these drugs stimulated
the development of new agents with safer pharmacological profile and
predominant local anti-inflammatory activity, such as budesonide (BUD)
[1,2]. Cyclodextrins (CD) have been used as adjuvants in different
pharmaceutical formulations due to their ability to form of inclusion
complexes. In special, the p-CD derivative,
2-hydroxypropyl-p-cyclodextrin (HP-β-CD), is an effective alternative
for complexation with poorly soluble drugs [3,4] such as BUD. For
pharmaceutical applications, it has been reported the development of
ternary complexes, i.e., comprising three different molecular entities.
Two of those compounds refer to the drug and CD, while the third one may
have different origins and purposes, such as natural or synthetic
polymers [5]. In addition to CD, polymers such as poloxamers (PL)
improve physico-chemical properties of the drug, as well as the
entrapment and the efficiency of release, also optimizing the cost,
toxicity and the production of the scaled-up pharmaceutical formulations
[4].
Poloxamers (PL) are triblock copolymers composed of polyethylene
oxide (PEO) and polypropylene oxide (PPO) units organized as PEO-PPO-PEO
structure. The numbers of PEO and PPO units as well as the PEO: PPO
ratio determine their structural and physico-chemical features
(molecular weight, hydrophilic- lipophilic balance-HLB and critical
micellar concentration-CMC). Due to their amphiphilic characteristics,
PL are able to selfassembly in micelles (when in aqueous solution above
their CMC) and also are thermoresponsive, as a result of the PPO
dehydration groups and micellar aggregation, forming hydrogels at a
critical gelation temperature (CGT). Those properties allow the PL
application in the chemical, cosmetic and pharmaceutical fields [6].
Among glucocorticoid drugs, BUD presents low aqueous solubility and
extensive first-pass biotransformation which are limitations for
administration by different routes. In order to develop new
pharmaceutical formulations able to increase the aqueous solubility and
to maintain the drug into the site of administration (specially into the
colonic region), in situ forming hydrogels have been proposed as
promising alternatives.
In fact, different components (drugs, tensoactives, organic solvents,
solubilizers) incorporated into PL-based formulations have directed
their investigations [7-11]. Then, to reach those goals, we present the
structural effects of the incorporation of BUD-HP-P- CD inclusion
complex into the PL-based thermoreversible hydrogels composed of PL 407
and PL 403, with hydrophilic lipophilic balances (HLB) of 22 and 8,
respectively. The formation of binary systems composed of hydrophilic
(PL407) and hydrophobic PL copolymers, can modulate physico-chemical and
biopharmaceutical properties (such as drug solubility and release
kinetics) [12]. Some reports have presented specific structural studies
about the interaction between CD and PL [13-19]. However, none of them
considered the possible interactions between drug: CD inclusion
complexes and PL-based binary systems with different
hydrophilic-lipophilic balances, such as PL407-PL403. Then, in this
article, we reported the effects of HP-β-CD, BUD or BUD-HP-β-CD
inclusion complex incorporation into PL 407 or PL407-PL403 hydrogels,
determined by Small Angle X-ray Scattering (SAXS) analysis, in order to
study the PL binary system phase organization mechanism and its
influence on the supramolecular structure of PL-based hydrogels as well
as to elaborate their association model.
Materials and Methods
Budesonide (BUD), 2-Hydroxypropyl-P-cyclodextrin (HP- P-CD),
Poloxamer 403 (Pluronic® P-123) and Poloxamer 407 (Pluronic® F-127) were
purchased from Sigma-Aldrich Chem. Co., NO, USA. All chemicals and
solvents were of analytical grade. In order to obtain the BUD: HP-β-CD
inclusion complex, HP-P- CD and BUD were mixed in water, at 1:1 drug: CD
molar ratio, homogenized for 24h (at 25 °C), lyophilized and stored at
-20 °C until use or incorporation into the PL-based systems. After that,
PL-based formulations were obtained by PL 407 (18 or 20 % m/v) isolated
or in association with PL403 (at 2 % m/v), in water, and kept at cold
bath under magnetic stirring (100 rpm) until complete polymer
dissolution. BUD was incorporated into the PL-systems at 0. 5 mg/mL and
BUD: HP-β-CD inclusion complex or HP-β-CD were added to the different
PL-formulations for obtaining the same final BUD concentration [12]. It
is noteworthy that the CD-PL systems were used in this study as a
comparison parameter (control) to the inclusion complex (CPX)-PL.
Morphological observations were performed using small angle X-ray
scattering (SAXS). The experiments were carried out at the D11A-SAXS1
beamline at the Brazilian Synchrotron Light Laboratory (LNLS) in Brazil.
A parallel X-ray beam irradiates a cylindrical sample holder. The
radiation wavelength was 1.55 A and a Pilatus detector at 936 mm
distance was used to give a scattering vector (q=4n/A.sin(0)), where 20
is the scattering angle ranging from 0.06 to 2.00 nm-1. Water
scattering curves were collected and subtracted from the samples
scattering curve, taking into account its attenuation. All the
measurements were performed at 25 °C.
Results and Discussion
Figure 1 shows the comparison of SAXS measurements for the PL407
systems at 18 % (1a), 20 % (1b) and its binary system at 18-2%
PL407-PL403 (3c). In general, the SAXS profiles showed a lamellar phase
organization, with spacing d=2n/qA* ~18nm, even after
insertion of BUD, HP-β-CD or their inclusion complex. In this context,
reports in the literature have shown that PL407 units (PPO units)
interact with the hydrophobic cavity of HP-β-CD and displace guest
molecules, such as drugs, leading to the formation of PL: CD
non-covalent complexes, named polypseudo rotaxanes [16,2022]. Although
it is known that beta CD can disturb the poloxamers micellar structure
by reducing the critical micellar concentration since it makes them more
hydrophilic [23], this effect is not expected for the system studied
here since the CD:PL molar ration were lower (~1:10) compared to the
literature (5:1) [22] and the PL407 and PL403 molecules have long PPG
chains. However, after insertion of BUD-HP-β-CD complex into the
PL-systems this phenomenon was not observed, since the high association
constant (Ka) value between BUD and HP-β-CD (K = 8662.8 M-1)
[12] reduces the possibility of the drug displacement from the HP-β-CD,
allowing the accommodation of the inclusion complex entities into the
lamellar PEO region.
In order to fit the SAXS data for low q, as shown in Figure 2, we apply
the model of a modified Ornstein-Zernike form, as used in the literature
[24-26] to describe I(q): presence of PL403 into the systems (1:4
PL403:PL407 molar ratio), since its low molecular weight (MW= 5800) and
shorter number of PEO units (PEO units = 39.2), compared to PL407 (MW =
12600 and PEO units = 200.5) [23], allowed the accommodation of those
components into the lamellae.
In this model we have four free parameters in addition to the amplitude
I(0): β is associated to the cluster size (Figure 3), 5 is
related to the primary-particle size, α is the mass fractal dimension, ƞ
is the surface fractal dimension. The values of β (cluster size) and ξ
(primary-particle size) for all the systems, are shown in the Table 1.
The values of the mass fractal dimension, a, for all the systems are the
same, 0.69 and the surface fractal dimension, ƞ, is 2.32. Finally,
other important point to be considered is regarding to PL final
concentration into the systems, resulting in different CD:PL molar
ratio, being 1:12 and 1:14 for PL407 systems at 18 % or 20 %,
respectively. In fact, different CD:PL ratios influenced on the
accommodation of HP-β-CD into the lamellae evoking pronouncing changes
in the primary-particle size, as observed in the Table 1, for all the
concentrations of PL 407, due to the interaction and aggregation of PL
unimers at higher concentrations. However, for the binary system the
insertion of BUD, HP-β-CD or BUD-HP- p-CD inclusion complex did not
evoke an evident change on the primary-particle size (Table 1). This
observation is resulting of th presence of PL403 into the systems (1:4
PL403:PL407 molar ratio), since its low molecular weight (MW= 5800) and
shorter number of PEO units (PEO units = 39.2), compared to PL407 (MW =
12600 and PEO units = 200.5) [23], allowed the accommodation of those
components into the lamellae.
Final Considerations
In this research, it was presented a study of the supramolecular
structure of the formation of the clusters for the PL407 systems as
unique or associations with other PL forming binary hydrogels
PL407/PL403 with budesonide, HP-β-CD and inclusion complex
budesonide-HP-β-CD, using SAXS to characterize the size of these
clusters. The SAXS measurement revealed a lamellar phase organization,
and using the modified Ornstein-Zernike, the form for the low q region
from SAXS data, we observe changes on cluster arrangement for different
systems with BUD, HP-β-CD and inclusion complex budesonide-HP-β-CD. In
this study, is possible to highlight that the primary-particle size, for
the PL407 18% systems, increases when we include the cyclodextrin and
the complex (displayed on Table 1). Moreover, for the highest PL407
concentration, the primary-particle size increases after CD
incorporation, being also observed similar effects after inclusion
complex addition into the hydrogels. In the case of the binary hydrogel
PL407/PL403, the primary-particle size almost remains constant. These
results suggest that after CDs incorporation into the hydrogels, their
hydrophobic cavity can interact with the polyethylene glycol chains
(PEG), suddenly increasing the primary-particle size.
On the other hand, for the inclusion complex (budesonide- HP-β-CD),
we have described other possible type of interaction. Considering that
the hydrophobic cavity of CD is occupied by budesonide, this complex can
possibly insert into the system amongst the PEG chains from PL,
observing a similar mechanism for those two systems.
Additionally, the cluster dimension for PL407 18% systems, decreased
after CD insertion, but increased when the complex was included into the
system. Those behavior was also observed for PL407 20% the cluster
decreases with the addition of CD and remains similar after inclusion
complex incorporation. In the binary hydrogel system, PL407/PL403, the
size of the cluster slightly decreases for both cases (with CD and with
the complex). The reduction of the cluster size when CD is added
suggests that the interactions between the primary-particles are
weakened due to the interaction between the hydrophobic cavity of CD and
the PEGC. In the case of the inclusion of the complex, the interactions
between the primary-particles remain similar, once the CD hydrophobic
cavity is already filled with the drug (BUD). On the other hand, the
binary system (PL407/PL403) the interaction between the particles for
the systems with CD remains the same, suggesting that the interaction of
the hydrophobic cavity of CD occurs with the PEG from PL403. Those
results are of great interest for drug-delivery fields to development of
new pharmaceutical formulations.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.